Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

EVMN earnings analysis

Filed May 7, 2026 · Our reading of the company's report

The latest report

Evommune reported zero revenue for Q1 2026, significantly missing expectations as incurred operating losses intensified, marking a 202% increase compared to the prior year. Despite the lack of revenue, the company holds…

Read full summary

Evommune reported zero revenue for Q1 2026, significantly missing expectations as incurred operating losses intensified, marking a 202% increase compared to the prior year. Despite the lack of revenue, the company holds a strong cash position of $307 million, expected to sustain operations through 2028, while continuing its crucial clinical trials with data expected in mid-2026.

Read the original on SEC.gov

Reported figures

Earnings per share
$-21.67

What stood out

  • Zero Revenue This Quarter

    Evommune reported no revenue for Q1 2026, a decline of $3.0 million (100%) compared to $3.0 million in Q1 2025.

  • Increased Operating Losses

    Net loss increased to $21.7 million for Q1 2026, up $7.1 million (49%) from $14.6 million in Q1 2025.

  • Maintained Strong Cash Position

    Cash, cash equivalents, and investments totaled $307 million at quarter-end, sufficient to fund operations through 2028.

  • Increased R&D Expenses

    Research and development expenses rose to $17.3 million in Q1 2026, an increase of $2.957 million (21%) from $14.4 million in Q1 2025.

  • Interest Income Boost

    Other income for Q1 2026 was $2.3 million, showing improvement from $0.5 million in Q1 2025, driven by higher interest income.

  • Financing Boost from Private Placement

    EVMN raised $117.2 million from the issuance of common stock in February 2026.

What to watch

  • Absence of Product Revenue

    The company has not generated any product-related revenue as of March 31, 2026, continuing its reliance on funding.

  • Increasing Operating Expenses

    Total operating expenses rose to $23.9 million for Q1 2026, up $5.9 million (33%) compared to Q1 2025.

  • Dependence on Future Financing

    Evommune anticipates needing significant additional funding in the future to continue clinical trials, as they have accumulated a deficit of $242.8 million.

Management's outlook

No forward guidance was provided.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.